SIM
ACAD icon

Spark Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Spark Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-57,700
Closed -$1.55M – 551
2019
Q1 		$1.55M Buy
+57,700
New +$1.35M 0.07% 288

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Spark Investment Management's ACAD Position: Q2 2019 in Review

Spark Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2019, closing a stake of 57,700 shares — an estimated $1.55M sold.

Spark Investment Management first reported a position in ACAD in Q1 2019 and held it in 1 quarter. The position peaked at $1.55M in Q1 2019. 196 funds tracked by Wall St. Rank hold ACAD as of Q2 2019.

  • Spark Investment Management reported no remaining Acadia Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Spark Investment Management sold 57,700 Acadia Pharmaceuticals shares in Q2 2019, an estimated $1.55M.
  • Spark Investment Management first reported a position in Acadia Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Spark Investment Management's Acadia Pharmaceuticals position peaked at $1.55M in Q1 2019.
  • 196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2019.

Based on Spark Investment Management's 13F filing for Q2 2019, filed 12 Aug 2019.